VT-1908
Asset
Inosine monophosphate dehydrogenase inhibitor that suppresses de novo purine synthesis in lymphocytes
- Stage
- Preclinical
- Modality
- Small molecule
- Target
- Inflammation
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Ocular inflammation
Preclinical, businesswire.com, 5 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Evidence for its targets1
- Competitors1
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.